These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28198785)

  • 41. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
    Khanani AM; Dugel PU; Haller JA; Wagner AL; Lescrauwaet B; Schmidt R; Bennison C
    J Comp Eff Res; 2020 Mar; 9(4):287-305. PubMed ID: 31961196
    [No Abstract]   [Full Text] [Related]  

  • 42. ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial.
    Tadayoni R; Holz FG; Zech C; Liu X; Spera C; Stalmans P
    Retina; 2019 Dec; 39(12):2341-2352. PubMed ID: 30308558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.
    Jackson TL; Haller J; Blot KH; Duchateau L; Lescrauwaet B
    Surv Ophthalmol; 2022; 67(3):697-711. PubMed ID: 34480895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
    Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM
    Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
    Morescalchi F; Gambicorti E; Duse S; Costagliola C; Semeraro F
    Expert Opin Drug Saf; 2016 Sep; 15(9):1267-78. PubMed ID: 27388220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.
    Steel DHW; Patton N; Stappler T; Karia N; Hoerauf H; Patel N; Wachtlin J; Raber T; Kozma-Wiebe P;
    Retina; 2021 Feb; 41(2):266-276. PubMed ID: 32496343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Portuguese Experience with Ocriplasmin in Clinical Practice.
    Figueira J; Martins D; Pessoa B; Ferreira N; Meireles A; Sampaio A; Carneiro Â; Vaz F; Nascimento J; Moreno N; Roque J; Domingues M; Flores R; Teixeira C; Conde E; Henriques F; Proença H; Pita Negrão J; Barbosa M; Silva R; Vaz-Pereira S; Pereira Neves P; Gomes N; Raimundo M;
    Ophthalmic Res; 2016; 56(4):186-192. PubMed ID: 27438077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flat Electroretinography and Acute Visual Loss After Ocriplasmin Injection for Vitreomacular Adhesion Complicating Macular Schisis.
    Hale BP; Au AK; Falk NS; Bhatnagar P; Beer PM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Sep; 46(8):888-92. PubMed ID: 26431307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome.
    Pirani V; Pelliccioni P; Cesari C; Carrozzi G; Cavallero E; Mariotti C
    Jpn J Ophthalmol; 2019 May; 63(3):255-261. PubMed ID: 30805734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Ocriplasmin on objectively assessed retinal function after treatment of vitreomacular diseases.
    Schatz A; Seuthe AM; Januschowski K
    Acta Ophthalmol; 2019 Aug; 97(5):e700-e705. PubMed ID: 30730114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.
    Gómez-Ulla F; Bande MF; Abraldes M
    Doc Ophthalmol; 2015 Dec; 131(3):231-5. PubMed ID: 26542118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes.
    Small KW; Shaya FS; La Fontaine M
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):956-62. PubMed ID: 26469236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.